查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854685

胃肠道疾病药物市场按适应症、药物类别、给药途径、通路、剂型和最终用户划分－2025-2032年全球预测

Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胃肠道疾病药物市场将成长至 577.1 亿美元，复合年增长率为 4.10%。

关键市场统计数据
基准年 2024 418.2亿美元
预计年份：2025年 435.2亿美元
预测年份 2032 577.1亿美元
复合年增长率 (%) 4.10%

这篇精闢的导言概述了正在重新定义胃肠道疾病治疗策略的临床、商业和营运动态。

胃肠道治疗领域正处于临床复杂性、技术创新以及不断变化的支付方和监管机构期望的交汇点。生物製药的研发、对微生物组的日益关注以及精准诊断的復兴，共同再形成了从酸相关疾病到发炎性肠道疾病等多种疾病的研发重点。同时，医疗系统要求提供更清晰的真实世界价值证据，这正在改变临床项目的规划方式和商业化策略的优先顺序。

在此背景下，相关人员必须兼顾短期营运挑战与长期治疗机会。供应链韧性、监管灵活性和差异化临床终点对计画的可行性日益重要。此外，以患者为中心的护理模式与数位医疗的融合正在重新定义慢性胃肠疾病的依从性、监测和疗效评估。因此，决策者需要一种综合观点，将临床创新与商业性可行性以及在医院、诊所和家庭医疗保健机构的实际应用联繫起来。

本执行摘要提炼了影响关键适应症和产品类别疗法开发、上市和市场准入的核心动态。它重点阐述了需求结构性变化、监管和政策影响，以及产业领导者可采取的行动要点。透过将临床趋势与营运和商业现实相结合，本概要旨在为企业高管和投资者提供一个聚焦的观点，以帮助他们确定投资重点、建立伙伴关係关係并加速提升患者获益。

全面、前瞻性地阐述了推动胃肠道药物研发和递送领域根本性变革的科学、监管和商业性因素。

胃肠道治疗领域正经历一场变革，其驱动力包括科学突破、监管改革和医疗模式的转变。首先，生物製药和标靶免疫调节剂的成熟正推动研发工作转向精准的作用机制研究，尤其是在发炎性肠道疾病领域，抗整合素抑制剂和白细胞介素抑制剂已彻底改变了治疗流程。同时，人们对肠道微生物组的重新关注也促进了对微生物组疗法和非传统治疗方法的投资，并有望开发出超越传统小分子化合物和质子帮浦抑制剂的新型治疗方法。

同时，监管机构正着重强调适应性路径和真实世界证据，并以此指导试验设计和上市后承诺。这种监管转变有利于那些在研发早期就整合可操作终点、纵向病患监测和卫生经济学分析的计画。此外，医院专科药房在复杂生技药品的供应方面继续发挥至关重要的作用。

最后，随着支付方日益重视可证明的价值和成本效益，商业性格局正在改变。製造商正透过创新定价和循证策略来应对，包括基于结果的合约和风险分担安排。总而言之，这些变化需要一项整合策略，才能将科学进步转化为永续的患者可及性和商业性成功。

对近期关税调整如何重塑胃肠道治疗药物供应链、生产决策和商业谈判进行策略评估

美国将于2025年实施新的关税，将对全球胃肠道治疗药物的供应链、筹资策略和成本结构产生连锁反应。关税调整可能会影响活性药物原料药的成本，尤其是那些从国际供应商采购的活性药物成分，从而加大依赖跨境生产或大宗原材料进口的製造商的价格压力。因此，各公司需要重新评估筹资策略和合约条款，以在确保产品品质和供应连续性的同时，保护净利率。

除了直接的成本影响外，关税还可能加速製造业地域布局和垂直整合的策略转变。企业可能会透过将关键中间体的生产转移到近岸地区、扩大国内契约製造或与供应商谈判签订长期合约来降低价格波动。这些应对措施通常需要资本投资和延长前置作业时间，这可能会影响临床供应和商业部署的时间表。此外，关税相关的成本增加可能会影响与支付方和医院系统的价格谈判，促使製造商积极投资于价值验证和真实世界证据，以证明其定价决策的合理性。

关税政策带来的不确定性也将影响投资者情绪和併购活动。有些投资者在进行重大交易前，会寻求更清晰的供应链风险缓解措施，而有些投资者则会将关税视为促进整合和策略伙伴关係的催化剂，以确保在地化生产。最终，采取多管齐下应对措施（包括供应商多元化、合约保护以及与支付方和购买方进行透明沟通）的公司，将更有能力应对累积影响，同时保障患者获得必要的胃肠道药物。

深入的細項分析，重点关注临床、製剂和管道方面的差异化因素，这些因素驱动着各个治疗类别的产品采纳路径和商业化重点。

细分市场层面的洞察揭示了不同适应症、药物类别、给药途径、分销管道、剂型和终端用户之间存在的细微机会和限制因素。同时，感染性胃肠炎涵盖细菌性、感染疾病和病毒性胃肠炎，这些疾病的急性期治疗和抗菌药物管理方案各不相同。发炎性肠道疾病分为克隆氏症和溃疡性大肠炎，二者的外科和生物治疗方案也不同。大肠激躁症分为便秘型、腹泻型和混合型，需要针对不同症状采取相应的治疗策略。

按药物类别划分，氨基水杨酸盐、抗生素、止泻药、解痉药、H2受体拮抗剂、泻药和质子帮浦阻断剂等传统药物类别继续满足核心治疗需求，而生物製药及其亚型，例如抗整合素药物、抗肿瘤坏死因子药物和白细胞介素抑制剂，则在中差异性发炎性疾病中展现出重度发炎的价值。在抗生素中，Ciprofloxacin、甲硝唑和Rifaximin等药物在治疗不同的感染病因方面各有其特异性作用，凸显了药物管理和抗药性监测的重要性。给药途径，无论是口服、注射或局部，都会影响病人的依从性、治疗环境要求、製剂创新重点。

分销管道，包括医院药房、线上药房和零售药房，各自不同的商业性和监管动态会影响报销、病患用药和依从性。剂型，包括注射液、口服粉剂、口服混悬液和胶囊剂，决定了生产的复杂性、低温运输要求以及给药方式创新的机会。最后，终端使用者细分，包括诊所、家庭医疗保健和医院，决定了新治疗方法的推广路径和培训需求。综上所述，这些细分洞察表明，成功的产品策略必须全面协调适应症特定的临床需求、差异化的分子类别、实际可行的给药途径和用途，以及针对特定管道和终端用户的商业化计划。

区域比较视角着重分析监管、支付方和基础设施的差异，这些差异影响全球市场准入、市场接受度和供应策略。

区域动态，反映了法律规范、医疗服务体系和患者群体方面的差异，对制定研发重点和市场推广策略至关重要。美洲地区拥有强大的临床研究基础设施、完善的支付体系和先进的专科医疗网络，为创新生技药品和复杂治疗方法的引入提供了支持，但同时也面临着严格的证据要求和价格压力。因此，製造商必须优先考虑可靠的临床终点和卫生经济学证据，以确保在这些市场中获得处方地位和报销。

在欧洲、中东和非洲，监管环境和报销机制的多样性既带来了机会，也带来了挑战。西方市场往往需要全面的疗效比较数据和基于价值的论证，而该地区的新兴市场则可能更注重可负担性和供应链的可靠性。同时，中东和非洲在医疗基础设施不断完善和慢性病负担日益加重的推动下，蕴藏着巨大的成长潜力，但每个地区都需要製定量身定制的准入策略，并充分考虑当地的采购流程。因此，采取协调一致的区域性方法，平衡集中式的证据产生和局部化的商业化策略至关重要。

亚太地区医疗保健投资的快速成长、生技药品生产基地的不断扩大以及法规结构的持续演进是该地区的关键主题。该地区的多个市场正在加强本地临床试验能力，并加速新型疗法的核准。如果与监管策略协调一致，这些措施可以缩短产品上市时间。然而，价格敏感度和多样化的报销机制要求采用弹性价格设定和合作模式。总而言之，区域策略必须考虑不同的监管预期、支付方行为以及医疗服务基础设施，才能将科学进步转化为病患可近的医疗保健服务。

整合企业策略和生态系统伙伴关係，揭示创新、製造和数位融合如何重塑该产业的竞争优势。

胃肠道治疗领域的公司层面动态反映了一系列策略态势，涵盖了从专注于创新的生物技术公司到大型製造商和专业合约服务提供者。创新公司致力于开发下一代生技药品、标靶小分子药物和微生物疗法，通常利用精准医疗方法和生物标记主导的临床试验来识别有效人群。这些公司正与临床研究网络和学术中心建立策略联盟，以加速概念验证试验并检验差异化的临床终点。

同时，现有製药公司和学名药企业正透过生命週期管理、生物相似药开发和製剂改进来优化其产品组合，从而提高患者的用药便利性和依从性。受託製造厂商）和专业CDMO正在拓展其能力，以支持注射用生技药品和复杂口服製剂的生产，这影响着申办方的产品上市速度和成本结构。在整个生态系统中，策略合作、授权协议和有针对性的收购仍然是补充内部能力和填补产品线缺口的常用机制。

最后，新兴企业和数位医疗领域的参与企业正在将远端监测、患者报告结果和依从性技术整合到其产品中，以增强真实世界证据的收集和价值展示。治疗药物研发企业和正在开发数位解决方案的合作伙伴正在加强上市后监测和与支付方的谈判。总而言之，那些能够将科学差异化与卓越营运、符合支付方需求的证据策略以及敏捷的商业化模式相结合的公司，将在竞争激烈的市场环境中占据优势。

以营运为导向的建议，整合供应链韧性、证据完整性和交付创新，以增强胃肠道治疗的临床和商业性成果。

行业领导者应采取一系列切实可行的措施，将科学进步转化为可持续的商业性成果和更佳的患者照护。首先，应优先考虑供应链韧性，透过多元化关键活性药物原料药的供应商，并协商灵活的合约来降低关税和地缘政治风险。投资于双重采购策略并加强与製造外包的关係，将有助于降低脆弱性，并确保临床和商业供应的连续性。

第二，透过早期参与终点指标、卫生经济学和真实世界证据的收集，使临床开发与支付方的期望保持一致，从而促进价值对话并支持处方谈判。第三，透过优化剂型和给药途径，提高病患依从性并支持居家照护，加速给药创新。

第四，我们将寻求策略联盟，整合我们在生技药品开发、微生物组科学和数位健康领域的优势，建构差异化的证据包和患者支持解决方案。第五，我们将采用灵活的商业化模式，根据当地通路动态调整分销策略，在与医院药局的合作以及零售药局和线上药局的通路拓展之间取得平衡。最后，我们将加强在监管策略、市场进入和商业分析方面的组织能力，以便快速应对政策变化和支付方需求的转变。这些措施将巩固我们的市场地位，并改善患者的治疗效果。

我们采用透明的多来源调查方法，结合文献综合、专家参与和情境分析，以检验我们的策略见解和建议。

本分析的调查方法整合了多方面的证据来源，并采用迭代检验步骤以确保其稳健性和有效性。首先，透过全面的二次检索，整合了同侪审查的临床文献、监管指南、专利申请和治疗指南，建立了关于治疗机制、临床终点和标准治疗实践的基准。这项基础研究确定了关键的知识空白，并为后续的初步研究指明了方向。

主要研究包括对临床专家、支付方代表、生产专家和商业领袖进行结构化访谈，以了解当前的实践模式、定价和报销观点以及营运限制。访谈结果与监管文件和已发表的临床试验结果进行交叉比对，以验证论点并消除差异。此外，也运用情境分析来评估供应链突发事件和政策影响，并考虑应对关税变化和生产中断的合理措施。

品质保证措施包括交叉检验资讯资讯来源、专家同行评审以及对假设和限制的透明记录。伦理考量包括保护受访者的隐私并遵守资料隐私标准。儘管我们尽一切努力确保全面覆盖，但使用者仍应结合不断变化的临床证据和政策发展来解读研究结果。因此，我们的调查方法结合了严谨的文献综述、相关人员参与和分析建模，旨在为决策者提供可操作的资讯。

简洁扼要的结论总结了策略要务，强调需要采取综合性的、兼顾本地实际情况的方法，将创新转化为对病人的影响。

总之，胃肠道治疗格局正受到多种因素的共同影响而重塑：生物製药和微生物组研究领域的科学创新、强调真实世界证据的监管环境、支付方对价值的不断变化以及供应链和政策变化带来的营运压力。应对这些变化需要整合策略。那些积极主动地将证据产生与支付方需求结合、实现供应链多元化并投资于给药创新技术的机构，将在改善患者疗效的同时，获得竞争优势。

此外，不同地区的监管和报销环境存在细微差异，因此一刀切的方法并不适用。量身定制的策略、灵活的製造地以及协作伙伴关係关係对于实现临床疗效和商业性永续性至关重要。这些倡议将共同建构一个更具韧性、以患者为中心的医疗生态系统，使其能够适应政策变化和不断发展的临床实践。

因此，我们鼓励相关人员将这些战略要务转化为具体倡议，优先考虑那些能够展现临床差异化、运营稳健性以及对支付方和医疗保健提供者俱有明显价值的计划，这将加速将科学突破转化为胃肠道疾病患者可及且有效的治疗方法。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 肠道菌丛治疗性介入在大肠激躁症治疗的应用日益广泛
  • 针对发炎性肠道疾病黏膜癒合策略的生技药品和生物相似药研发管线的成长
  • 扩大口服小分子激酶抑制剂在克隆氏症和溃疡性大肠炎治疗的应用
  • 用于早期检测胃肠道癌症的非侵入性诊断生物标记的研究进展
  • 在大肠直肠癌治疗方案选择中，对采用基因谱分析的个人化医疗方法的需求日益增长。
  • 居家远端医疗监测和数位药物依从性工具在慢性胃肠道疾病的应用
  • 加强製药公司和生物技术公司之间的策略联盟，以实现基于微生物组的治疗方法的商业化
  • 增加对下一代胜肽疗法的投资，以解决功能性消化不良和胃轻瘫的症状

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以适应症分類的胃肠道疾病药物市场

  • 与酸相关的疾病
    • 消化不良
    • 胃食道逆流症
    • 消化性溃疡
  • 传染性肠胃炎
    • 细菌性肠胃炎
    • 寄生虫感染疾病
    • 病毒性肠胃炎
  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 大肠激躁症
    • 便秘是主要
    • 腹泻是主要症状。
    • 混合型

9. 按药物类别分類的胃肠道疾病药物市场

  • 氨基水杨酸盐
  • 抗生素
    • Ciprofloxacin
    • 甲硝唑
    • Rifaximin
  • 止泻
  • 解痉药
  • 生物製药
    • 抗整合素药物
    • 抗肿瘤坏死因子药物
    • 白细胞介素抑制剂
  • H2受体拮抗剂
  • 泻药
  • 质子帮浦抑制剂

第十章 依给药途径分類的胃肠道疾病药物市场

  • 口服
  • 肠外
  • 话题

第十一章 胃肠道疾病药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 胃肠道疾病药物市场（依剂型划分）

  • 注射液
  • 口服粉剂
  • 口服悬浮液
  • 片剂 胶囊

第十三章：依最终使用者分類的胃肠道疾病药物市场

  • 诊所
  • 家庭医疗保健
  • 医院

第十四章：各地区胃肠道疾病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 胃肠道疾病药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国胃肠道疾病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Novartis AG
    • Ferring BV
    • Gilead Sciences, Inc.
    • Bausch Health Companies Inc.
    • AstraZeneca PLC
    • UCB SA
Product Code: MRR-957C47F91DC1

The Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 57.71 billion at a CAGR of 4.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 41.82 billion
Estimated Year [2025] USD 43.52 billion
Forecast Year [2032] USD 57.71 billion
CAGR (%) 4.10%

An incisive introduction outlining evolving clinical, commercial, and operational dynamics that are redefining therapeutic strategies across gastrointestinal disease care

The gastrointestinal therapeutics landscape sits at the intersection of clinical complexity, technological innovation, and evolving payer and regulatory expectations. Advances in biologics, growing attention to the microbiome, and a resurgence in precision diagnostics have collectively reshaped development priorities for conditions ranging from acid-related disorders to inflammatory bowel disease. At the same time, healthcare systems are demanding clearer evidence of real-world value, which is changing how clinical programs are designed and how commercialization strategies are prioritized.

Against this backdrop, stakeholders must reconcile short-term operational challenges with long-term therapeutic opportunity. Supply chain resiliency, regulatory agility, and differentiated clinical endpoints are increasingly central to program viability. Moreover, patient-centric care models and digital health integrations are redefining adherence, monitoring, and outcome measurement for chronic gastrointestinal conditions. Consequently, decision-makers need an integrated view that links clinical innovation with commercial viability and practical deployment in hospitals, clinics, and home healthcare environments.

This executive summary distills core dynamics shaping therapeutic development, delivery, and market access across key indications and product classes. It highlights structural shifts in demand, regulatory and policy influences, and actionable imperatives for industry leaders. By synthesizing clinical trends with operational and commercial realities, the narrative aims to equip executives and investors with a focused perspective for prioritizing investment, structuring partnerships, and accelerating patient impact.

A forward-looking synthesis of scientific, regulatory, and commercial forces that are driving fundamental transformation across gastrointestinal therapeutics development and delivery

The landscape of gastrointestinal therapeutics is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing care models. First, the maturation of biologic platforms and targeted immunomodulators is redirecting R&D toward precise mechanisms of action, particularly for inflammatory bowel disease where anti-integrin agents and interleukin inhibitors have altered treatment algorithms. At the same time, renewed interest in the gut microbiome has catalyzed investment in microbiome therapeutics and nontraditional interventions, which promise new modalities beyond classic small molecules and proton pump inhibitors.

Concurrently, regulatory authorities are emphasizing adaptive pathways and real-world evidence, which is shaping study design and post-market commitments. This regulatory shift favors programs that integrate pragmatic endpoints, longitudinal patient monitoring, and health economics analyses early in development. Moreover, the distribution and delivery models are evolving; telehealth and remote patient monitoring are increasing the feasibility of home healthcare administration for selected therapies, while hospital-based specialty pharmacies continue to play a pivotal role for complex biologics.

Finally, commercial dynamics are shifting as payers insist on demonstrable value and cost-effectiveness. Manufacturers are responding with innovative pricing and evidence-generation strategies, including outcomes-based contracting and risk-sharing arrangements. Taken together, these shifts demand integrated strategies that span clinical development, regulatory engagement, supply chain planning, and payer dialogue in order to translate scientific advances into sustainable patient access and commercial success.

A strategic assessment of how recent tariff shifts reshape supply chains, manufacturing decisions, and commercial negotiations for gastrointestinal therapeutics

The introduction of new tariff measures in the United States in 2025 has implications that ripple across global supply chains, procurement strategies, and cost structures for gastrointestinal therapeutics. Tariff adjustments influence the cost of active pharmaceutical ingredients, particularly those sourced from international suppliers, and can increase the price pressure on manufacturers who rely on cross-border manufacturing and bulk raw material imports. Consequently, firms must reassess sourcing strategies and contract terms to preserve margins while maintaining product quality and continuity of supply.

In addition to direct cost implications, tariffs can accelerate strategic shifts in manufacturing geography and vertical integration. Companies may respond by nearshoring production of key intermediates, expanding domestic contract manufacturing capacity, or negotiating longer-term supplier agreements to dampen price volatility. These operational responses often require capital expenditure and longer lead times, and they can also affect timelines for clinical supply and commercial rollouts. Moreover, tariff-related cost increases may influence pricing negotiations with payers and hospital systems, prompting manufacturers to invest proactively in value demonstrations and real-world evidence to justify pricing decisions.

Policy uncertainty stemming from tariff regimes also impacts investor sentiment and M&A activity. Some investors may demand clearer visibility on supply chain risk mitigation before committing to sizeable transactions, while others may view tariffs as a catalyst for consolidation and strategic partnerships that secure localized manufacturing. Ultimately, companies that adopt a multifaceted response-combining supplier diversification, contractual protections, and transparent engagement with payers and purchasers-will be better positioned to manage the cumulative impacts while protecting patient access to essential gastrointestinal therapies.

Detailed segmentation analysis highlighting clinical, formulation, and channel differentiators that determine adoption pathways and commercialization priorities across therapeutic categories

Segment-level insights reveal nuanced opportunities and constraints across indications, drug classes, routes of administration, distribution channels, dosage forms, and end users. In indications, acid-related disorders encompass dyspepsia, gastroesophageal reflux disease, and peptic ulcer disease each with distinctive diagnostic and treatment patterns, while infectious gastroenteritis spans bacterial gastroenteritis, parasitic infections, and viral gastroenteritis that differ in acute management and antimicrobial stewardship implications. Inflammatory bowel disease bifurcates into Crohn's disease and ulcerative colitis with divergent surgical and biologic treatment pathways, and irritable bowel syndrome divides into constipation-predominant, diarrhea-predominant, and mixed type presentations that require personalized symptom-targeted approaches.

From a drug class perspective, traditional categories such as aminosalicylates, antibiotics, antidiarrheals, antispasmodics, H2 receptor antagonists, laxatives, and proton pump inhibitors continue to serve core therapeutic needs, while biologics and their subtypes-including anti-integrin agents, anti-tumor necrosis factor agents, and interleukin inhibitors-drive differentiated value in moderate-to-severe inflammatory conditions. Among antibiotics, agents like ciprofloxacin, metronidazole, and rifaximin play specific roles in treating distinct infectious etiologies, which underscores the importance of stewardship and resistance monitoring. Routes of administration, whether oral, parenteral, or topical, influence patient adherence, care setting requirements, and formulation innovation priorities.

Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each impose different commercial and regulatory dynamics that affect reimbursement, patient access, and adherence. Dosage form considerations-injectable solution, oral powder, oral suspension, and tablet capsule-shape manufacturing complexity, cold chain needs, and opportunities for delivery innovation. Finally, end-user segmentation including clinics, home healthcare, and hospitals frames adoption pathways and training requirements for new therapies. Taken together, these segmentation insights suggest that successful product strategies must be tailored across indication-specific clinical needs, differentiated molecule classes, pragmatic route and dosage considerations, and channel- and end-user-specific commercialization plans.

Comparative regional perspectives that illuminate regulatory, payer, and infrastructure variations shaping access, adoption, and supply strategies across global markets

Regional dynamics are pivotal in shaping development priorities and market access strategies, reflecting differences in regulatory frameworks, healthcare delivery systems, and patient demographics. In the Americas, strong clinical research infrastructure, established payer systems, and advanced specialty care networks support the uptake of innovative biologics and complex therapeutic regimens, while also presenting stringent evidence requirements and pricing pressures. As a result, manufacturers must prioritize robust clinical endpoints and health economics evidence to secure formulary placement and reimbursement in these markets.

In Europe, Middle East & Africa, regulatory diversity and varied reimbursement environments create both opportunities and challenges. Western European markets tend to demand comprehensive comparative effectiveness data and value-based narratives, while emerging markets in the region may prioritize affordability and supply chain reliability. Meanwhile, the Middle East and Africa present growth potential tied to expanding healthcare infrastructure and rising chronic disease burden, yet they require tailored access strategies and sensitivity to local procurement processes. Coordinated regional approaches that balance centralized evidence generation with localized commercialization tactics are therefore essential.

Across Asia-Pacific, rapid growth in healthcare investment, an expanding biologics manufacturing base, and evolving regulatory frameworks are key themes. Several markets in the region are enhancing local clinical trial capabilities and accelerating approvals for novel therapies, which can shorten time-to-market when regulatory strategies are well aligned. Nevertheless, price sensitivity and diverse reimbursement mechanisms necessitate flexible pricing and partnership models. In sum, regional strategies must account for distinct regulatory expectations, payer behaviors, and healthcare delivery infrastructures to convert scientific advances into accessible patient care.

A synthesis of corporate strategies and ecosystem partnerships that reveal how innovation, manufacturing, and digital integration are reshaping competitive advantage in the sector

Company-level dynamics in gastrointestinal therapeutics reflect a spectrum of strategic postures from innovation-focused biotechs to large-scale manufacturers and specialized contract service providers. Innovator organizations concentrate on advancing next-generation biologics, targeted small molecules, and microbiome-based interventions, often leveraging precision medicine approaches and biomarker-driven trials to delineate responder populations. These companies frequently pursue strategic partnerships with clinical research networks and academic centers to accelerate proof-of-concept studies and to validate differentiated clinical endpoints.

Meanwhile, established pharmaceutical manufacturers and generic producers are optimizing portfolios through life-cycle management, biosimilar development, and formulation enhancements that improve patient convenience and adherence. Contract manufacturing organizations and specialty CDMOs are expanding capacity to support both injectable biologics and complex oral formulations, which affects speed-to-market and cost structures for sponsors. Across the ecosystem, strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms to complement internal capabilities and to fill pipeline gaps.

Finally, emerging companies and digital health entrants are integrating remote monitoring, patient-reported outcomes, and adherence technologies into product offerings, thereby enhancing real-world evidence collection and value demonstration. Collaboration between therapeutic developers and digital partners is strengthening post-market surveillance and payer negotiations. In aggregate, companies that blend scientific differentiation with operational excellence, payer-aligned evidence strategies, and agile commercialization models will be better positioned to succeed within this competitive landscape.

Operationally focused recommendations that integrate supply chain resilience, evidence alignment, and delivery innovation to strengthen clinical and commercial outcomes in gastrointestinal therapeutics

Industry leaders should adopt a set of pragmatic actions to convert scientific progress into durable commercial outcomes and improved patient care. First, prioritize supply chain resilience by diversifying suppliers of critical active pharmaceutical ingredients and negotiating flexible contracts to mitigate tariff-related and geopolitical risks. Investing in dual-source strategies and strengthening relationships with contract manufacturers will decrease vulnerability and preserve continuity of clinical and commercial supply.

Second, align clinical development with payer expectations through early engagement on endpoints, health economics, and real-world evidence generation. Implement adaptive trial designs and pragmatic studies that reflect clinical practice patterns; this will facilitate value conversations and support formulary negotiations. Third, accelerate delivery innovation by optimizing dosage forms and routes of administration that improve adherence and enable home-based care, while also exploring companion diagnostic strategies to target therapies to likely responders.

Fourth, pursue strategic collaborations that combine strengths across biologics development, microbiome science, and digital health to build differentiated evidence packages and patient support solutions. Fifth, adopt flexible commercialization models that tailor distribution strategies to local channel dynamics, balancing hospital pharmacy partnerships with retail and online pharmacy access where appropriate. Finally, enhance organizational capabilities in regulatory strategy, market access, and commercial analytics to ensure swift adaptation to policy shifts and evolving payer demands. Collectively, these steps will strengthen market positioning and improve patient outcomes.

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and scenario analysis to validate strategic insights and recommendations

The research methodology underlying this analysis integrated multiple evidence streams and iterative validation steps to ensure robustness and relevance. Initially, comprehensive secondary research synthesized peer-reviewed clinical literature, regulatory guidance, patent filings, and treatment guidelines to establish a factual baseline for therapeutic mechanisms, clinical endpoints, and standard-of-care practices. This foundational work identified key knowledge gaps and informed subsequent primary research priorities.

Primary research included structured interviews with clinical experts, payer representatives, manufacturing specialists, and commercial leaders to capture contemporary practice patterns, pricing and reimbursement perspectives, and operational constraints. Insights from these interviews were triangulated with regulatory filings and published clinical trial results to validate assertions and to reconcile divergent viewpoints. In addition, scenario analyses were applied to assess supply chain contingencies and policy impacts, enabling exploration of plausible responses to tariff changes and manufacturing disruptions.

Quality assurance measures involved cross-validation of sources, peer review by subject-matter experts, and transparent documentation of assumptions and limitations. Ethical considerations included confidentiality protections for interview participants and adherence to data privacy standards. While every effort was made to ensure comprehensive coverage, users should interpret insights in the context of evolving clinical evidence and policy developments. The methodology thus combines rigorous literature synthesis, stakeholder engagement, and analytic modeling to produce actionable intelligence for decision-makers.

A concise conclusion that synthesizes strategic imperatives and reinforces the need for integrated, regionally aware approaches to convert innovation into patient impact

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by converging forces: scientific innovation in biologics and microbiome research, regulatory emphasis on real-world evidence, evolving payer expectations for value, and operational pressures stemming from supply chain and policy changes. Navigating these shifts requires integrated strategies that span early clinical design, manufacturing planning, and market access negotiations. Organizations that proactively align evidence generation with payer needs, diversify supply chains, and invest in delivery innovation will secure competitive advantage while enhancing patient outcomes.

Moreover, regional nuances in regulatory and reimbursement environments mean that a one-size-fits-all approach is insufficient. Tailored regional strategies, agile manufacturing footprints, and collaborative partnerships will be critical to achieving both clinical impact and commercial sustainability. The cumulative effect of these actions is to create a more resilient and patient-centered therapeutic ecosystem that can respond to policy shifts and evolving clinical practice.

Stakeholders are therefore encouraged to convert these strategic imperatives into concrete initiatives-prioritizing projects that demonstrate clinical differentiation, operational robustness, and clear value to payers and providers. Doing so will accelerate the translation of scientific breakthroughs into accessible, effective therapies for patients living with gastrointestinal diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of microbiome therapeutic interventions in irritable bowel syndrome management
  • 5.2. Growth of biologics and biosimilars pipeline targeting inflammatory bowel disease mucosal healing strategies
  • 5.3. Expansion of oral small molecule kinase inhibitors for treatment of Crohn's disease and ulcerative colitis
  • 5.4. Advancements in noninvasive diagnostic biomarkers for early detection of gastrointestinal cancers
  • 5.5. Rising demand for personalized medicine approaches leveraging genetic profiling in colorectal cancer therapy selection
  • 5.6. Emergence of home-based telehealth monitoring and digital adherence tools for chronic gastrointestinal disorders
  • 5.7. Increased strategic partnerships between pharma and biotech for microbiome-based therapy commercialization
  • 5.8. Growing investment in next-generation peptide therapies addressing functional dyspepsia and gastroparesis symptoms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Diseases Therapeutics Market, by Indication

  • 8.1. Acid-Related Disorders
    • 8.1.1. Dyspepsia
    • 8.1.2. Gastroesophageal Reflux Disease
    • 8.1.3. Peptic Ulcer Disease
  • 8.2. Infectious Gastroenteritis
    • 8.2.1. Bacterial Gastroenteritis
    • 8.2.2. Parasitic Infections
    • 8.2.3. Viral Gastroenteritis
  • 8.3. Inflammatory Bowel Disease
    • 8.3.1. Crohn's Disease
    • 8.3.2. Ulcerative Colitis
  • 8.4. Irritable Bowel Syndrome
    • 8.4.1. Constipation-Predominant
    • 8.4.2. Diarrhea-Predominant
    • 8.4.3. Mixed Type

9. Gastrointestinal Diseases Therapeutics Market, by Drug Class

  • 9.1. Aminosalicylates
  • 9.2. Antibiotics
    • 9.2.1. Ciprofloxacin
    • 9.2.2. Metronidazole
    • 9.2.3. Rifaximin
  • 9.3. Antidiarrheals
  • 9.4. Antispasmodics
  • 9.5. Biologics
    • 9.5.1. Anti Integrin Agents
    • 9.5.2. Anti Tumor Necrosis Factor Agents
    • 9.5.3. Interleukin Inhibitors
  • 9.6. H2 Receptor Antagonists
  • 9.7. Laxatives
  • 9.8. Proton Pump Inhibitors

10. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

  • 12.1. Injectable Solution
  • 12.2. Oral Powder
  • 12.3. Oral Suspension
  • 12.4. Tablet Capsule

13. Gastrointestinal Diseases Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Healthcare
  • 13.3. Hospital

14. Gastrointestinal Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastrointestinal Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastrointestinal Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Takeda Pharmaceutical Company Limited
    • 17.3.4. Pfizer Inc.
    • 17.3.5. Novartis AG
    • 17.3.6. Ferring B.V.
    • 17.3.7. Gilead Sciences, Inc.
    • 17.3.8. Bausch Health Companies Inc.
    • 17.3.9. AstraZeneca PLC
    • 17.3.10. UCB SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GASTROINTESTINAL